Semaglutide Composition & Biomarkers

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) is a synthetic GLP-1 receptor agonist containing 31 amino acids with a fatty acid side chain that extends its half-life in the body. The active ingredient semaglutide mimics the natural hormone glucagon-like peptide-1, which regulates blood sugar and appetite signaling in the brain.

Understanding semaglutide's composition matters because the drug's effectiveness depends not only on its chemical structure but also on how individual genetic variations in GLP-1 receptors and related metabolic pathways may influence response. PlexusDx's precision-wellness approach includes assessing these genetic predispositions alongside clinical history to support more tailored treatment conversations with your provider.

The Active Ingredient and Molecular Structure of Semaglutide

Semaglutide is a 31-amino-acid peptide hormone analog manufactured through recombinant DNA technology. It contains a palmitic acid side chain attached to lysine at position 26, which allows the molecule to bind to albumin in the bloodstream and extend its pharmacokinetic half-life from hours to approximately one week.

This structural modification enables once-weekly dosing in injectable formulations and once-daily dosing in oral preparations. The fatty acid moiety slows gastric emptying and systemic absorption, maintaining therapeutic concentrations over extended periods while reducing injection frequency compared to earlier GLP-1 agents.

Inactive Ingredients and Formulation Differences Across Ozempic Delivery Forms

Beyond semaglutide itself, Ozempic injection contains sodium chloride, sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, and water for injection. These excipients maintain pH, osmolality, and stability. Oral semaglutide (Rybelsus) uses different inactive ingredients including sodium caprate and sodium bicarbonate to enhance intestinal absorption.

Component	Purpose	Ozempic Injection	Rybelsus (Oral)
Active ingredient	GLP-1 receptor agonism	Semaglutide 1-2.4 mg/mL	Semaglutide 3, 7, 14 mg tablet
Preservative system	Microorganism control	Metacresol 1.5 mg/mL	None (blister packaging)
Osmolality agents	Solution tonicity	Sodium chloride, phosphates	Sodium bicarbonate, caprate
Stabilizers	Molecular integrity	Phosphate buffer	Croscarmellose, microcrystalline cellulose
Delivery mechanism	Bioavailability optimization	Subcutaneous injection pen	Oral tablet on empty stomach

How Semaglutide's Mechanism Relates to Individual Metabolic Variation

Semaglutide binds to GLP-1 receptors on pancreatic beta cells, intestinal L-cells, and brain neurons. This binding stimulates insulin secretion when blood glucose rises, slows gastric emptying, and activates satiety centers in the hypothalamus. Clinical response depends partly on the drug's pharmacokinetics and partly on individual receptor sensitivity and expression.

Genetic variations in the GLP1R gene (such as rs6923761) can influence how efficiently semaglutide activates its target receptor. Similarly, variants in the MC4R gene affect appetite regulation, and FTO polymorphisms relate to baseline metabolic rate. These predispositions may provide context for why some individuals experience greater weight reduction or improved glycemic control than others.

Safety Considerations and Who Should Evaluate Semaglutide Treatment

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Common side effects include nausea, vomiting, and diarrhea during dose escalation. Risk of pancreatitis, gallbladder disease, and diabetic retinopathy complications requires medical supervision.

A qualified healthcare provider should assess your full medical history, current medications, and metabolic biomarkers before starting treatment. Understanding your genetic predispositions in peptide pathways can support this conversation, but should never replace individualized clinical evaluation. PlexusDx's Precision Peptide Genetic Test provides baseline predisposition data that providers can discuss within the context of your overall health profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in the GLP1R, GIPR, FTO, and MC4R genes—pathways directly involved in how semaglutide and other GLP-1 agonists function. This information may help provide context about your metabolic predispositions and how your body's natural peptide signaling systems are genetically configured. Understanding these predispositions should be interpreted with a qualified healthcare provider as part of a comprehensive treatment discussion.

The genetic test reveals predispositions in peptide genetic pathways, not exact medication response or guaranteed outcomes. A favorable GLP1R variant does not guarantee superior weight loss or glucose control with semaglutide; conversely, a less-favorable variant does not mean the medication will be ineffective. Genetics is one layer of personalization; clinical history, comorbidities, lifestyle, and drug-drug interactions remain essential determinants of real-world outcomes.

When considering whether compounded semaglutide or another GLP-1 option fits your health goals, discussing your genetic predispositions with your provider can support a more nuanced, informed conversation. PlexusDx connects this genetic context to accessible compounded formulations, helping bridge the gap between precision assessment and practical treatment access at transparent pricing.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Semaglutide Composition & Biomarkers | PlexusDx